Zim Laboratories announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO) for its novel fixed-dose combination (FDC) of Naproxen Delayed Release and Esomeprazole capsules (375 mg/500 mg + 20 mg/20 mg).
More NewsSELECT INDEX : December 03, 2025
|
HIGH
85,269.68() |
LOW
84,763.64() |
PREVIOUS
85,138.27() |
+91 40 4436 3699 / 3600
GIFT Nifty indicates flat opening for equities
December 03, 2025 8:25 AM